Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Change in Receivables (2022 - 2025)

Historic Change in Receivables for Mirum Pharmaceuticals (MIRM) over the last 4 years, with Q3 2025 value amounting to $3.1 million.

  • Mirum Pharmaceuticals' Change in Receivables fell 6116.05% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.9 million, marking a year-over-year increase of 9284.4%. This contributed to the annual value of $11.4 million for FY2024, which is 7401.65% down from last year.
  • Mirum Pharmaceuticals' Change in Receivables amounted to $3.1 million in Q3 2025, which was down 6116.05% from $9.1 million recorded in Q2 2025.
  • Mirum Pharmaceuticals' 5-year Change in Receivables high stood at $20.1 million for Q4 2023, and its period low was -$13.0 million during Q1 2024.
  • For the 4-year period, Mirum Pharmaceuticals' Change in Receivables averaged around $7.0 million, with its median value being $7.7 million (2022).
  • In the last 5 years, Mirum Pharmaceuticals' Change in Receivables surged by 43293.57% in 2023 and then crashed by 204437.78% in 2024.
  • Quarter analysis of 4 years shows Mirum Pharmaceuticals' Change in Receivables stood at $7.7 million in 2022, then surged by 162.95% to $20.1 million in 2023, then crashed by 46.04% to $10.9 million in 2024, then tumbled by 71.04% to $3.1 million in 2025.
  • Its Change in Receivables stands at $3.1 million for Q3 2025, versus $9.1 million for Q2 2025 and $16.8 million for Q1 2025.